CGEM Logo

Cullinan Oncology, Inc. (CGEM) 

NASDAQ
Market Cap
$962.99M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
486 of 776
Rank in Industry
258 of 433

Largest Insider Buys in Sector

CGEM Stock Price History Chart

CGEM Stock Performance

About Cullinan Oncology, Inc.

Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of …

Insider Activity of Cullinan Oncology, Inc.

Over the last 12 months, insiders at Cullinan Oncology, Inc. have bought $0 and sold $3.9M worth of Cullinan Oncology, Inc. stock.

On average, over the past 5 years, insiders at Cullinan Oncology, Inc. have bought $19.31M and sold $8.69M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 8,090 shares for transaction amount of $100,316 was made by AHMED NADIM (President and CEO) on 2022‑06‑06.

List of Insider Buy and Sell Transactions, Cullinan Oncology, Inc.

2024-09-05SaleChief Scientific Officer
8,000
0.0139%
$18.09$144,720-6.64%
2024-07-05SaleChief Scientific Officer
8,000
0.0137%
$16.33$130,6400.00%
2024-05-07SaleChief Scientific Officer
5,606
0.0138%
$30.06$168,516-38.63%
2024-05-06SaleChief Scientific Officer
58,000
0.1331%
$28.07$1.63M-36.55%
2024-02-01SaleChief Business Officer
40,000
0.104%
$16.18$647,200+1.97%
2024-01-29SaleChief Business Officer
40,000
0.0901%
$14.09$563,600+21.72%
2024-01-23SaleChief Business Officer
21,316
0.0493%
$12.46$265,597+41.37%
2024-01-22SaleChief Business Officer
18,684
0.0431%
$12.14$226,911+44.90%
2023-12-26SalePresident and CEO
4,272
0.0096%
$9.24$39,473+82.05%
2023-12-21SaleChief Scientific Officer
1,145
0.0024%
$8.50$9,733+84.44%
2023-12-21SaleChief Financial Officer
1,920
0.004%
$8.50$16,320+84.44%
2023-12-21SaleChief Medical Officer
1,860
0.0039%
$8.50$15,810+84.44%
2023-12-21SaleChief Legal Officer
1,400
0.0029%
$8.50$11,900+84.44%
2023-12-18SaleChief Scientific Officer
238
0.0005%
$8.22$1,956+92.63%
2023-12-18SaleChief Financial Officer
398
0.0008%
$8.22$3,272+92.63%
2023-12-18SaleChief Medical Officer
386
0.0008%
$8.22$3,173+92.63%
2023-12-18SaleChief Legal Officer
290
0.0006%
$8.22$2,384+92.63%
2023-12-12SaleChief Scientific Officer
1,068
0.0025%
$7.81$8,341+120.86%
2023-12-12SaleChief Financial Officer
1,926
0.0045%
$7.81$15,042+120.86%
2023-06-28SalePresident and CEO
759
0.0019%
$11.40$8,653-3.47%

Insider Historical Profitability

1.26%
AHMED NADIMPresident and CEO
111550
0.1924%
$16.6115<0.0001%
Trigilio JeffreyChief Financial Officer
83919
0.1447%
$16.61112<0.0001%
UBS Oncology Impact Fund L.P.10 percent owner
7648268
13.192%
$16.61118<0.0001%
LAMPERT MARK N
4058854
7.0008%
$16.6130+15.29%
Jovan-Embiricos Morana
1281952
2.2112%
$16.6113<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Bioimpact Capital Llc$130.33M13.277.65M0%+$021.09
Bvf Inc Il$54.47M5.553.2M0%+$00.4
Blue Owl Capital Holdings Lp$49.84M5.082.92M-14.47%-$8.43M4.17
Franklin Templeton Investments$45.95M4.682.7M-17.81%-$9.96M0.01
BlackRock$41.39M4.212.43M-1.35%-$567,108.26<0.01
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.